Objectives: To evaluate functional outcomes following Aquablation in various prostate volume and anatomical subgroups.

Design: A meta-analysis with individual patient data undergoing Aquablation therapy from four prospective, global, clinical studies that have been conducted with Aquablation; WATER, WATER II, FRANCAIS WATER and OPEN WATER.

Setting: Australia, Canada, Lebanon, Germany, New Zealand, UK and the USA.

Participants: 425 men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) with 1-year follow-up.

Interventions: Aquablation therapy is an ultrasound guided, robotically executed waterjet ablative procedure for the prostate.

Main Outcome Measures: The analyses focus International Prostate Symptom Score (IPSS), uroflowmetry, postoperative Incontinence Severity Index (ISI) and surgical retreatment.

Results: 425 men with prostates ranging in size from 20 to 150 mL underwent Aquablation therapy. The outcomes from the seven questions in the IPSS questionnaire were grouped by the following; prostates <100 mL, prostates ≥100 mL, prostate anatomy with an obstructive median lobe identifed by imaging, and prostate anatomy without an obstructive median lobe. Regardless of subgroup, all outcomes are consistent and demonstrate a significant improvement from baseline. Specifically, improvements in frequency, urgency and nocturia demonstrated bladder function improvement. Patients entering treatment with severe incontinence, ISI score >4, and regardless of prostate size, showed a reduction in incontinence during patient follow-up. Surgical retreatment due to BPH symptoms occurred in 0.7% (95% CI 0.1%-2.0%).

Conclusions: Across a variety of prostate anatomies, Aquablation therapy showed remarkable functional improvements following the index procedure. Additionally, men with moderate to severe LUTS/BPH and overactive bladder resulting in urge incontinence showed a reduction in incontinence symptoms postprocedure.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749268PMC
http://dx.doi.org/10.1136/bmjsit-2021-000090DOI Listing

Publication Analysis

Top Keywords

aquablation therapy
16
meta-analysis individual
8
functional outcomes
8
outcomes aquablation
8
lower urinary
8
urinary tract
8
tract symptoms
8
prostate anatomies
8
reduction incontinence
8
aquablation
7

Similar Publications

Introduction: Water Jet Ablation Therapy (WJAT) and Holmium Laser Enucleation of the Prostate (HoLEP) represent two common surgical treatments for Benign Prostatic Hyperplasia (BPH). Despite their increasing use, there is no study between these two methods. We aim to evaluate their efficacy and safety through a network meta-analysis (NMA), providing critical insights for clinical decision-making in the management of moderate to severe lower urinary tract symptoms (LUTS) due to BPH.

View Article and Find Full Text PDF

Objectives: To evaluate the safety, efficacy, and patient-reported outcomes of Aquablation therapy using the AQUABEAM Robotic System for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) in a Japanese population.

Methods: This post-market use-results survey included 103 Japanese men with BPH who underwent Aquablation across five centers with previously Aquablation naïve physicians. Data were collected at baseline, during the procedure, at discharge, and at 3 and 6 months post-procedure.

View Article and Find Full Text PDF

Introduction: Morphological changes in the prostatic urethra and bladder cavity resulting from Aquablation treatment are still unknown. This study aims to assess the safety and efficacy of Aquablation within one-year post-surgery, focusing on both functional and endoscopic outcomes.

Methods: Prospective enrollment of patients undergoing Aquablation (10/2018-04/2023) included those with baseline International Prostate Symptom Score (IPSS) ≥ 10, prostate volume from 40 to 80 mL, and Qmax ≤ 12 mL/s.

View Article and Find Full Text PDF

The Safety and Feasibility of Aquablation in Patients with Previous Surgery for Benign Prostatic Hyperplasia.

J Endourol

January 2025

USC Institute of Urology and Catherine & Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.

Aquablation for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) has been adopted to treat a wide range of prostate anatomies including glands up to 150 cc. Patients with recurrence of LUTS after previous BPH procedure often present with variant anatomy, and a paucity of literature exists on the optimal treatment modality for these patients. Herein, we evaluate the safety and feasibility of aquablation in patients with previous BPH surgical history.

View Article and Find Full Text PDF

[AQUABLATION OF THE PROSTATE - A NOVEL ROBOTIC PROCEDURE FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA].

Harefuah

July 2024

Department of Urology, Chaim Sheba Medical Center, Tel Hashomer, Ramat-Gan, Israel, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Article Synopsis
  • Aquablation is a new robotic-assisted procedure using ultrasound and water jets to treat benign prostatic hyperplasia (BPH), aiming to assess its efficiency and safety.
  • A retrospective analysis of 50 patients revealed successful surgeries with no intra-operative complications, a median surgery time of 51 minutes, and minimal change in hemoglobin levels.
  • The procedure led to a significant improvement in urinary symptoms and quality of life, with most patients showing stable functional outcomes and none reporting significant urinary incontinence post-surgery.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!